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ABSTRACT 
 The Centers for Disease Control and Prevention deemed the increase in overdose 
fatalities, due to the use of opioids, an “opioid epidemic” in the United States. Heroin, 
fentanyl, and other synthetic opioids are commonly abused and are contributing to the 
opioid epidemic.  In 2016, the Drug Enforcement Administration temporarily placed 
three fentanyl analogs (beta-hydroxythiofentanyl, butyryl fentanyl, and furanyl fentanyl) 
under Schedule I due to their imminent threat to public health.  These drugs elicit 
analgesic effects similar to heroin making them desirable drugs to abuse.  Novel fentanyl 
analogs and designer opioids are expected to become more prominent in forensic 
casework in the near future as the opioid epidemic continues.  These drugs can be seen in 
forensic seized drug and urine casework samples either alone or mixed with other drugs 
of abuse.  It is therefore necessary to have an efficient methodology to identify these new 
compounds.  Currently, gas chromatography-mass spectrometry (GC/MS) is used to 
identify drugs of abuse and is considered the “gold standard” in forensic casework.  
However, analysis times can often range from 15 to 60 minutes in length.  Another 
drawback is the need for spectral library matching, which requires analytical reference 
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materials for identification.  Therefore, the identification of novel fentanyl analogs and 
designer drugs is limited until a reference material becomes available. 
In this study, direct sample analysis time-of-flight mass spectrometry (DSA-
TOFMS) was evaluated to provide rapid identification of fentanyl and other synthetic 
opioids in seized drug and urine casework samples.  DSA is a direct ambient ionization 
source, which requires no chromatography and minimal sample preparation.  TOFMS is a 
high resolution mass spectrometer that uses collision-induced dissociation (CID) to 
produce precursor ion and characteristic fragmentation ions, which provide additional 
structural and molecular formula information, allowing for the identification of 
compounds without a reference material.  The analytes explored in this study include: 
heroin, 6-monoacetylmorphine (6-MAM), morphine, fentanyl, norfentanyl, 4-anilino-N-
phenethylpiperidine (4-ANPP), acetyl fentanyl, beta-hydroxythiofentanyl, butyryl 
fentanyl, furanyl fentanyl, valeryl fentanyl, AH-7921, U-47700, buprenorphine, 
norbuprenorphine, desomorphine, MT-45, W-15, and W-18. 
Direct sample analysis time-of flight mass spectrometry (DSA-TOFMS) is a 
novel instrumentation that could be utilized in the forensic sciences field to qualitatively 
identify illicit substances in casework samples.  In this study, 19 compounds of interest 
containing heroin, fentanyl, fentanyl analogs, and other synthetic opioids were evaluated 
using DSA-TOFMS.  DSA-TOFMS abbreviated the workload of the analysis and was 
utilized to provide precursor ion and characteristic fragmentation ions within an analysis 
time of 20 seconds.  Certified reference standards were used to optimize instrumentation 
settings, to determine precursor ions and characteristic fragmentation ions, and to 
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determine the limit of detection of the instrument.  A carryover study determined there 
were no persisting ions present when entering the capillary inlet between runs.  A 
repeatability study revealed the DSA-TOFMS repeated results within the acceptable 
criteria range of above 500 counts and within 10ppm error 93% (10ppm) and 83% 
(1ppm).  Forensic seized drug casework samples were evaluated with DSA-TOFMS and 
qualitatively identified.  Out of the 64 samples, 89% were qualitatively identified as 
heroin, 4% were qualitatively identified as fentanyl, 1% was qualitatively identified as 
heroin and fentanyl, 3% were qualitatively identified as acetyl fentanyl, and 3% were 
qualitatively identified as furanyl fentanyl.  The casework samples containing furanyl 
fentanyl were considered “true unknown unknown samples,” as the Maine Health and 
Environmental Testing Laboratory gas chromatography-mass spectrometry library did 
not have a spectrum to use for the identification of these samples.  Forensic urine 
casework samples were evaluated with DSA-TOFMS.  Samples previously confirmed to 
contain compounds of interest were prepared using minimal sample preparation 
technique (filtered using 0.45 microns syringe filters and diluted (1:10) with LC/MS 
grade water).  Analysis displayed the limitations of DSA-TOFMS as only twelve of the 
forty compounds of interest were present and only three of the twelve were within the 
acceptable criteria range. 
DSA-TOFMS is a fast and reliable technique with minimal sample preparation for 
forensic seized drug samples.  However, the concentration in complex matrixes, such as 
urine and blood, were unable to be qualitatively identified using this sample preparation 
method by DSA-TOFMS.  
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1. INTRODUCTION 
1.1 Opioids Chemistry and Background 
 Opiates are the naturally found alkaloid compounds in the opium poppy plant 
Papaver somniferum (1).  They are broadly classified as opioids which is also the 
terminology used to describe synthesized compounds that act on the same receptors to 
elicit similar effects. Opioids act on the brain and body by attaching to specific proteins 
called opioid receptors (mu, delta, and kappa) found in the brain, spinal cord, and 
gastrointestinal tract (2).  This interaction blocks the perception of pain; however, opioids 
can produce drowsiness, nausea, constipation, and respiration depression (1).  Opioids 
induce euphoria by affecting the brain regions that mediate what is perceive as pleasure 
(1).  This feeling is often intensified for those who abuse opioids through intravenous and 
insufflation administration (2).  When the administration of opioids is repeated, the 
production of endogenous opioids (endorphins) is inhibited contributing to habitual use 
and withdrawal symptoms when opioids are not administered (2).  
1.1.1 Opioid Epidemic 
 Opioids are commonly prescribed by medical professionals to manage acute and 
chronic pain.  However, the rates at which opioids are prescribed are inconsistent across 
the United States, which demonstrates a lack of consensus among medical professionals 
on how opioid pain medication should be prescribed (3).  This inconsistency has led to 
the over prescription of opioid medication, allowing these drugs to be commonly abused.  
Every day, over 1,000 people are treated in emergency departments for misusing 
prescription opioids (4).  The amount of prescription opioids prescribed by medical 
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professionals has quadrupled since 1999, which directly correlates with overdose 
fatalities involving prescription opioids (4).  In 2012, the Centers for Disease Control and 
Prevention (CDC) reported that “health care providers wrote 259 million prescriptions for 
opioid pain medication, which is enough for every adult in the United States to have a 
bottle of pills” (3).  The awareness of over prescribing opioids in the medical field has 
increased, making it harder for individuals, who abuse prescription opioids, to obtain 
them (5).  The DEA has also begun hosting the National Prescription Drug Take-Back 
Day in September 2010 which allows certain DEA registrants, such as manufacturers, 
distributors, reverse distributors, narcotic treatment programs, retail pharmacies, and 
hospital/clinics with an on-site pharmacy, to become authorized collectors of unused, 
expired, or unwanted prescriptions (5).  In turn, the street value of prescription opioids 
has increased ($1/mg) forcing users to turn to a cheaper street alternative: heroin 
($0.50/mg) (6).  For example, one 80 mg pill of oxycodone would cost $80 compared to 
$40 for 80 mg of heroin.  In 2015, 63.1% of overdose fatalities (33,091 of 52,000) 
involved a prescription or illicit opioid (3).  The CDC states that every day, 91 Americans 
die from an opioid overdose, and has deemed the increase in overdose fatalities an opioid 
epidemic in the United States (7).  Heroin, fentanyl, and the development of novel 
synthetic opioids has increased, contributing to the continuation of the opioid epidemic. 
1.1.2 Heroin 
 Heroin, also known as diamorphine, is an opioid first synthesized in 1874 by C. 
R. Alder Wright from morphine (1). Morphine is a naturally occurring substance that is 
extracted from the seed of the opium poppy plant (1).  Heroin is prepared by the isolation 
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and acetylation of morphine (1).  Heroin is listed as a Schedule I drug on the Controlled 
Substance Act (CSA) due to a high potential for abuse and lack of currently accepted 
medical use (8).  It can be administered intravenously, inhaled, smoked, or snorted.  
Heroin is unlikely to be detected in urine specimens due to the rapid hydrolysis to 6-
monoacetylmorphine and the slower hydrolysis to morphine.  Due to heroin’s half-life of 
approximately three minutes, the presence of 6-monoacetylmorphine (6-MAM) is used as 
a marker for heroin use (9).  
 Heroin is abused for its euphoric effects.  Within 20 seconds of heroin being 
administered intravenously, it will have crossed the blood-brain barrier with ~70% of the 
administered dose reaching the brain (9).  Doses for heroin vary, depending on the route 
of administration.  Smoking doses range from 15 to 30 mg, intravenous doses range 
between 5 and 30 mg, and ingestion doses range from 50 to 70 mg (1).  The minimum 
lethal dose is 200 mg, but habitual users may be able to endure ten times as much because 
a tolerance to the drug builds quickly (9).  An increase in dose, increases the likelihood of 
drug overdose.  Heroin is associated with more accidental overdoses and fatal poisonings 
than any other scheduled substance (9). 
 A heroin overdose may be treated with naloxone.  Naloxone is an 
opioid antagonist that binds to opioids receptors and works rapidly to reverse the 
symptoms associated with an opioid overdose (10).  Currently, due to the prevalence of 
overdoses in the United States, many law enforcement officers carry naloxone on their 
persons to administer if heroin is suspected (6).  Treatment of heroin addiction often 
includes behavioral therapy and medications (11).  These medications may include 
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methadone (a slow-acting opioid agonist), buprenorphine (a partial opioid agonist) or 
naltrexone (an opioid antagonist) (11).  Withdrawal symptoms of heroin include 
sweating, malaise, anxiety, depression, general feeling of heaviness, excessive yawning 
or sneezing, tears, rhinorrhea, insomnia, cold sweats, chills, severe muscle and bone 
aches, nausea, vomiting, diarrhea, cramps, watery eyes, fever and cramp-like pains and 
involuntary spasms in the limbs which may occur 6-24 hours after discontinuing the use 
of heroin (12).  
1.1 3 Fentanyl 
 Fentanyl is a synthetic opioid originally developed as an analgesic and anesthetic.  
Fentanyl is listed as a Schedule II drug on the CSA due to a high potential for abuse 
which may lead to severe psychological or physical dependence (13).  Fentanyl is used 
medically in hospital settings as an anesthetic during surgeries and to treat chronic pain. 
It is also administered as a transdermal patch, lozenge, or nasal spray for cancer patients 
or patients with persistent pain (14).  The transdermal patch’s therapeutic dose is 
approximately 12 to 100μg/hour (14).  The lozenge’s therapeutic dose is approximately 
200μg/0.25hr/4hours (14).  The nasal spray’s therapeutic dose is approximately 
100μg/dose (14).  The estimated lethal dose of fentanyl is 2 milligrams (14). 
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Figure 1: Lethal Dose of Fentanyl.  Comparison of 2mg of fentanyl to the size of a penny (4). 
  
 Although fentanyl can be obtained through prescriptions, it is currently the 
clandestinely manufactured fentanyl that is abused.  Fentanyl is abused in the United 
States due to its similar analgesic effects to heroin; however fentanyl is 40-50 times more 
potent than heroin, contributing to the increase of overdoses across the United States 
(11).  In 2013, the DEA reported around 550 fentanyl-related overdose fatalities 
according to multi-state death reports (15).  These fatalities increased to over 2,000 
deaths in 2014 and again in 2015 (15).  Fentanyl can be mixed into heroin products or 
pressed into counterfeit prescription pills (11).  
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Figure 2: Counterfeit Prescription Pills Containing Fentanyl.  Oxycodone pills pressed with fentanyl 
found in Tennessee (4). 
 
The National Forensic Laboratory Information System (NFLIS) reported 93% of 
confiscated fentanyl mixed with other drugs was mixed with heroin from January to June 
of 2014 (16).  The mixing of heroin and fentanyl is often done without the users’ 
awareness which leads to overdose incidents.  The high demand for prescription 
medications is being exploited by traffickers who produce and sell counterfeit 
prescription medication containing fentanyl (6).  Counterfeit prescription medications 
have been reported to contain anywhere from 0.6 to 6.9 milligrams of fentanyl per pill 
(6). 
 Fentanyl is not only dangerous to the users who abuse the drug but also to law 
enforcement officers and first responders (17).  Fentanyl is easily absorbed through the 
skin and individuals who may come in contact with powders containing this substance in 
the field can experience multiple adverse health effects, such as disorientation, coughing, 
sedation, respiratory depression or cardiac arrest (18).  Rigidity of the chest muscles also 
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known as "wooden chest syndrome" may occur when encountered, which interferes with 
normal breathing (18).  The onset of these effects is very rapid usually occurring within 
minutes of exposure (18).  Depending on the scene they are responding to, law 
enforcement officers should be wary of individuals opening bags containing fentanyl 
making the powder airborne and able to be inhaled.  Canine units are susceptible to death 
if fentanyl is inhaled (17).  Precautions should be in place if field tests are utilized to 
determine a preliminary identification of fentanyl (17).  Field tests can be performed in a 
public area, on the street, in a home, or in the officer’s vehicle which increases the 
amount of contact the officer has with the substance putting potentially themselves and 
those around them in danger (17).  As of June 2016, the DEA issued a warning that 
fentanyl exposure kills and advising law enforcement to exercise extreme caution (17).  
The DEA suggests law enforcement officers should avoid all bare skin contact, to not 
field test the substance, and submit substances directly to the laboratory for testing (17). 
1.1.4 Novel Synthetic Opioids 
 Due to the DEA’s scheduling of fentanyl, fentanyl analogs and designer synthetic 
opioids are being synthesized and sold on the street to evade prosecution.  These fentanyl 
analogs and designer synthetic opioids have contributed to the 72.2% increase of fatal 
overdoses from 2014 to 2015 (19). These opiates are difficult to analyze in forensic 
laboratories due to the lack of certified reference materials, lack of spectral libraries, and 
the unknown effects these unidentified substances may have on the user.  
 Fentanyl analogs of concern in forensic science include 4-anilino-N-
phenethylpiperidine (4-ANPP), acetyl fentanyl, beta-hydroxythiofentanyl, butyryl 
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fentanyl, furanyl fentanyl, and valeryl fentanyl.  4-ANPP is a precursor in the illicit 
production of fentanyl, acetyl fentanyl, and possibly other fentanyl analogs and therefore 
is Schedule II under the CSA Precursor Act (20).  The synthesis of fentanyl converts 4-
ANPP to fentanyl utilizing Siegfried method (20).  4-ANPP is also a metabolite of 
fentanyl and possibly the metabolite of other fentanyl analogs due to similarities in 
chemical structure (20).  Acetyl fentanyl, beta-hydroxythiofentanyl, butyryl fentanyl, and 
furanyl fentanyl are Schedule I under the CSA (8).  As of February of 2017, valeryl 
fentanyl has not been scheduled.  
 Due to the increase abuse of opioids, designer synthetic versions are expected to 
become more prevalent.  Research drugs, such as AH-7921 (CSA I), MT-45 (not 
scheduled), U-47700 (CSA I), W-15 (not scheduled) and W-18 (not scheduled) have 
become compounds of interest due to their abuse or expected abuse in upcoming years 
(8).  Due to the timeline of cases presenting themselves, publishing process in academic 
journals, and legislation, the identification of designer synthetic drugs can be challenging 
for forensic laboratories (21).  However, legislation in the form of federal register notices 
are issued through the DEA frequently to temporarily place synthetic designer drugs on 
the CSA (22, 23, 24, 25). 
1.1.5 Current Methods 
 The marquis reagent in a field test kit is commonly used to screen for illicit 
substances in the field by law enforcement officers.  Heroin will produce a purple violet 
color change and fentanyl will produce an orange color change (26, 27).  Due to the 
similarities in structure, fentanyl analogs will also produce an orange color change.  
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These field tests are fast, inexpensive, and require little training to use.  However, these 
field tests are subjective, and, when more than one compound is present, are unreliable. 
 The current confirmatory methods in forensic sciences include gas 
chromatography-mass spectrometry (GC/MS) and liquid chromatography-mass 
spectrometry (LC/MS).  These techniques require a spectral library and/or reference 
standards to compare with unknown samples.  These techniques utilize chromatography 
to separate complex matrices for analysis.  The gold standard for the analysis of 
controlled substances and urine specimens is GC/MS due to extensive reference libraries 
(28).  However, the GC/MS analysis can be a time consuming process that lasts anywhere 
from 15 to 60 minutes, depending on the method utilized. 
1.2 Novel Instrumentation 
 DSA-TOFMS is a novel instrumentation.  DSA is a direct ambient ionization 
source, requiring no chromatography and minimal sample preparation (29).  TOFMS is a 
high resolution mass spectrometer that uses collision-induced dissociation (CID) to 
produce precursor ion and characteristic fragmentation ions that provide additional 
structural and molecular formula information, allowing for identification of compounds 
without a reference material (29).  
1.3.1. Direct Sample Analysis Theory 
 Direct sample analysis uses atmospheric pressure chemical ionization (APCI) to 
ionize samples (29).  This soft ionization technique allows for the detection of precursor 
ion and characteristic fragmentation ions (29).  A tuning solution with known exact 
masses are introduced to the instrument through the liquid inlet (Figure 1) where it is 
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mixed and heated with the nebulization gas and auxiliary gas (29).  This hot solution is 
then sprayed through a corona needle at the sample (29).  The sample, which is spotted 
onto mesh target screens between the corona needle of the DSA and the inlet to the mass 
spectrometer, is ionized (Figure 2). The ionized particles are then drawn into the mass 
spectrometer for analysis (29). 
 
Figure 3: Direct Sample Analysis Schematic. The tuning solution is introduced to the instrumentation through the 
liquid inlet where it is mixed and heated with the nebulization gas and auxiliary gas. This hot solution is then sprayed 
through a corona needle at the sample. This ionizes the sample and the ionized particles are drawn into the mass 
spectrometer for analysis (29).  ©2012-2017 PerkinElmer, Inc.  All rights reserved.  Printed with permission. 
 
Figure 4: The Ionization Cascade. This is the chemistry cascade in which the sample are ionized through atmospheric 
pressure chemical ionization (30). 
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1.3.2. Time-of-Flight Theory 
 Ionized particles are drawn from the source into the flight tube of the mass 
spectrometer (29).  Particles, which were ionized at the ion source, travel through a flight 
tube and are reflected into a detector (29).  These ions have the same charge, same kinetic 
energies, and are traveling the same distance through the flight tube, which is kept at a 
constant voltage (29).  As such the amount of time an ion travels directly proportional to 
the mass to charge ratio (m/z) of an ion and, coupled with the known masses of the 
calibrators in the tuning solution, allows for accurate mass of the ionized particles to be 
determined (Figure 3) (29).  In the analysis of samples, two calibrator ions (121.0509 and 
622.0290) are locked on to which allows for accurate mass to be determined relative to 
these lock mass ions. 
 
Figure 5: Schematic of Time-of-Flight Mass Spectrometry. This depiction shows the ionized particles traveling thru 
the flight tube and into the detector. The red ion travels the flight tube in a shorter amount of time then the green ion 
due to its decrease in mass. Demonstrating the time the ion travels in the flight tube is directly proportional to the mass 
to charge ratio of the ion. 
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1.2.3. Forensic Application 
 With the ever changing drug market, designer drugs and analogs are considered to 
be “unknown unknowns”.  These are compounds that have not previously been seen in 
the forensic laboratory before; therefore, there is no reference spectrum on file, making a 
positive identification challenging.  In forensic drug chemistry and toxicology, there is a 
need for fast, simple methodology to analyze these unknown unknowns.  Current 
techniques use reference libraries and can take anywhere from 15 to 60 minutes to run 
one sample, depending on the method.  These unknown unknowns may not be identified 
in forensic casework owing to the sample preparation utilized.  
1.4 Research Objectives 
 The fundamental goal of this research was to evaluate the utility of DSA-TOFMS 
in forensic casework, specifically in the qualitative identification of fentanyl and other 
synthetic opioids that are posing, or could pose a threat to public safety.  The 19 
compounds of interest listed in Figure 6 were evaluated on the DSA-TOFMS in five 
aspects: detection of compounds, carryover, limit of detection, repeatability of results, 
and application to forensic casework samples.  
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Acetyl Fentanyl 
Valeryl Fentanyl 
Butyryl Fentanyl 
Acetyl Fentanyl 
Norfentanyl 
4-ANPP 6-Monoacetylmorphine 
Morphine 
AH-7921 
Desomorphine 
MT-45 Norbuprenorphine 
Buprenorphine 
Fentanyl Furanyl Fentanyl Heroin 
U-47700 W-18 W-15 
Beta-Hydroxythiofentanyl 
Figure 6: Chemical Structures of Compounds of Interest. 
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Figure 71: Solution being pipetted onto 
mesh target screens (29).  ©2012-2017 
PerkinElmer, Inc.  All rights reserved.  Printed 
with permission. 
2. MATERIALS AND METHODS 
2.1 Detection of Compounds of Interest 
 Certified reference material from Cerilliant (Round Rock, TX) and from Cayman 
Chemical (Ann Arbor, MI) in 10 ppm solutions 
made with LC/MS grade water (ThermoFisher 
Scientific; Waltham, MA) were analyzed using 
DSA-TOFMS to optimize instrumentation 
parameters.  Five microliters of 10 ppm solutions 
were spotted onto mesh target screens (Figure 5).  Two settings were varied to determine 
the optimized instrument parameters: capillary exit voltage and acquisition rate.  The 
capillary exit voltage was evaluated at 120V, 170V, 175V and 180V for all 19 
compounds to determine optimal voltage for the highest amplitude of precursor ion with 
characteristic fragmentation ions.  Characteristic fragmentation patterns were not present 
or below 500 counts at 120V. At 180V, the distinguishing ions between AH-7921 and U-
47700 were below 1000 counts. Capillary exit voltage of 170V and 175V were 
comparable with precursor ions however 175V had a higher amplitude for fragmentation 
ions. Therefore, the optimal capillary voltage of 175V was used in this evaluation. The 
acquisition rate was varied at 1 spectrum/sec, 5 spectra/sec, and 10 spectra/sec. The 
optimal acquisition rate of 5 spectra/sec provided the least amount of noise with the 
highest amplitude of ions of interest. Therefore, 5 spectra/sec was used in this evaluation. 
 The following parameters were the optimized settings: DSA conditions: corona 
current (5 µA), APCI heater temperature (325°C), auxiliary gas (N2) pressure (80 psi), 
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drying gas (N2) temperature (25°C).  The TOFMS was run in positive ion mode with a 
flight tube voltage of -10,000V.  Negative ion mode was not evaluated in this study.  The 
capillary exit voltage was set to 175V for MS analysis.  Mass spectra were acquired with 
a mass range of 85-2000 m/z and an acquisition rate of 5 spectra/sec.  To maintain mass 
accuracy, the APCI tuning mix locked two mass ions (121.0509, 622.0290) for analysis.  
These two mass ions were chosen because they flanked the mass region of interest and 
did not share precursor ion or characteristic fragmentation ions with the compounds of 
interest.  All samples were analyzed for 20 seconds.  The resulting spectra were evaluated 
using TOF Driver software (PerkinElmer, Version 6.2 (6.2.0.0147), utilizing the 
molecular formula and ppm error software feature (AxION EC ID).  TOF Driver 
generates a list of molecular formulae and associated ppm error based on the accurate 
mass and characteristic isotopic pattern present in the spectrum.  This allows for the 
identification of a compound without obtaining reference materials with an associated 
ppm error.  Table 1 contains products and identifiers used throughout this study. 
Table 1: Products and Identifiers.  
Product Company Identifier 
DSA-TOFMS PerkinElmer Serial #: DSAN14092902 
APCI Tuning Mix PerkinElmer Lot #: A711336 
Mesh Target Screens PerkinElmer P/N MZ305382 Rev D 
 VWR Eppendorf and 
Socorex Ultra Micro pipette 
tips Eppendorf Lot #: 522C4 
LC/MS grade water ThermoFisher Scientific Lot # SHBG6792V 
4-ANPP Cayman Chemical Batch: 0477298-15 
6-Monoacetylmorphine Cerilliant Lot #: FE07141402 
Acetyl Fentanyl Cerilliant Lot #: FN08271501 
AH-7921 Cayman Chemical Batch: 0482560-1 
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Beta-hydroxythiofentanyl Cayman Chemical Batch: 0482914-4 
Buprenorphine Cerilliant Lot #: 1009000010 
Butyryl Fentanyl Cayman Chemical Batch: 0450679-58 
Desomorphine* Cayman Chemical Batch 0457723-10 
Fentanyl Cerilliant Lot #: FE04231502 
Furanyl Fentanyl Cayman Chemical Batch: 1475993-34 
Heroin Cerilliant Lot #: FE05181501 
Morphine Cerilliant Lot #: FE080411-01 
MT-45 Cayman Chemical Batch:0482621-3 
Norbuprenorphine* Cerilliant Lot #: 032015SP 
Norfentanyl Cayman Chemical Batch: 0468467-7 
U-47700 Cayman Chemical Batch:0479029-1 
Valeryl Fentanyl Cayman Chemical Batch: 0478105-27 
W-15 Cayman Chemical Batch: 0477965-9 
W-18 Cayman Chemical Batch: 0477966-4 
 
2.2 Carryover Study 
 A carryover study was performed to determine if the 19 compounds of interest 
were persisting after ionization when entering the capillary inlet.  . It was conducted by 
running LC/MS grade water blanks in between compounds of interest.  Five microliters 
of water solution were pipetted onto a mesh target screen and analyzed with DSA-
TOFMS.  The resulting spectra were evaluated by the analyst in TOF Driver utilizing 
AxION EC ID.  Confirmation criteria included ±10 ppm error or less with presence of 
precursor ion and at least two characteristic fragmentation ions.  
2.3 Limit of Detection Study 
 A limit of detection study was completed to determine the lowest concentration 
the DSA-TOFMS could detect.  Criteria for successful detection was determined to be the 
presence of precursor ion and characteristic fragmentation ions. 0.1ppm, 0.05ppm, and 
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0.01ppm concentrations for a minimum of 10 replicates for each compound of interest 
were evaluated.  Five microliters of target compound solutions were pipetted onto a mesh 
target screen and analyzed.  The resulting spectra were evaluated in TOF Driver utilizing 
AxION EC ID.  Confirmation criteria included ± 10 ppm error or less with presence of 
precursor ion and characteristic fragmentation ions. 
2.4 Repeatability Study 
 A repeatability study was conducted to determine the accuracy and precision of 
the DSA-TOFMS.  Criteria for successful detection was determined to be the presence of 
precursor ion, presence of characteristic fragmentation ions, and a ppm error of ±10 or 
below.  Twenty replicates of 1 and 10ppm solutions of compounds of interest were 
prepared.  Five microliters of solutions were then pipetted onto a mesh target screen and 
analyzed with DSA-TOFMS.  The resulting spectra were evaluated in TOF Driver 
utilizing the molecular formula and ppm error feature.  Confirmation criteria included 
±10 ppm error or less with presence of precursor ion and characteristic fragmentation 
ions.  
2.5 Forensic Seized Drug Casework Samples 
 The Maine Health and Environmental Testing Laboratory’s (HETL) Forensic 
Chemistry Section provided 64 forensic seized drug casework samples for evaluation 
with DSA-TOFMS.  All samples were de-identified.  Approximately 1-2 mg (qualitative 
of powder from seized drug casework samples were diluted with 3mL of LC/MS grade 
water.  Five microliters of solutions were then pipetted onto a mesh target screen and 
analyzed.  The resulting spectra were evaluated in TOF Driver utilizing AxION EC ID.  
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Confirmation criteria included ±10 ppm error or less with presence of precursor ion and 
characteristic fragmentation ions.  
2.6 Forensic Urine Casework Samples 
 The Maine HETL’s Forensic Chemistry Section provided six forensic urine 
casework samples for analysis with DSA-TOFMS.  All samples were de-identified.  
These six samples were specifically chosen because GC/MS results revealed the presence 
of compounds of interest.  Five milliliters of urine was used for GC/MS analysis with 
compound specific solid phase extraction preparation method.  For the DSA-TOFMS 
analysis, a positive control spiked with fentanyl and a negative control were also prepared 
and run with the six casework samples.  Sample preparation for all samples included 
filtration of 2mL samples with a syringe filter (5mL and 0.45microns by Whatman) and 
diluted with LC/MS grade water (1:10).  Five microliters of sample solution was then 
pipetted on to mesh target screens in the following order: positive control, blank, negative 
control, blank, urine sample 1, blank, urine sample 2, blank, urine sample 3, blank, urine 
sample 4, blank, urine sample 5, blank, urine sample 6, blank.  The resulting spectra were 
evaluated in TOF Driver utilizing AxION EC ID, and compared to GC/MS results. 
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3. RESULTS  
3.1 Detection of Compounds of Interest Study 
 Settings were optimized and utilized to determine the precursor ion and 
characteristic fragmentation ions for the 19 compounds of interest.  The following mass 
spectra were acquired.  
 
Figure 8: Representative spectrum of 4-ANPP.  4-ANPP at 10ppm; ppm error: -0.361. 
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Figure 9: Representative Spectrum of 6-MAM.  6-MAM at 10ppm; ppm error: -0.158. 
 
Figure 10: Representative Spectrum of Acetyl Fentanyl.  Acetyl Fentanyl at 10ppm; ppm error: -0.517. 
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Figure: 11 Representative Spectrum of AH-7921.  AH-7921 at 10ppm; ppm error: 0.392. 
 
Figure 12: Representative Spectrum of Beta-hydroxythiofentanyl.  Beta-hydroxythiofentanyl at 10ppm; ppm error: -0.422. 
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Figure 13: Representative Spectrum of Buprenorphine.  Buprenorphine at 10ppm; ppm error: -0.174. 
 
Figure 14: Representative Spectrum of Butyryl Fentanyl.  Butyryl Fentanyl at 10ppm; ppm error: -1.62. 
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Figure 15: Representative Spectrum of Desomorphine.  Desomorphine at 10ppm; ppm error: -0.889. 
 
Figure 16: Representative Spectrum of Fentanyl.  Fentanyl at 10ppm; ppm error: -0.168. 
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Figure 17: Representative Spectrum of Furanyl Fentanyl.  Furanyl Fentanyl at 10ppm; ppm error: 0.129. 
 
Figure 18: Representative Spectrum of Heroin.  Heroin at 10ppm; ppm error:-0.886. 
1 0 5 . 0 7 2 9  
1 8 8 . 1 4 5 0  
3 7 5 . 2 0 6 7  
6 2 2 . 0 2 9 0  
0
2 5 0 0
5 0 0 0
7 5 0 0
1 0 0 0 0
1 2 5 0 0
1 5 0 0 0
1 7 5 0 0
5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0 6 0 0 6 5 0
M a ss
R E T  ( 0 0 . 2 0 1 2 5 )
A
m
p
li
t
u
d
e
m / z
C u r v e  1
Furanyl Fentanyl 
Heroin 
121.0509 
25 
 
Figure 19: Representative Spectrum of Morphine.  Morphine at 10ppm; ppm error: 1.34. 
 
 
Figure 20: Representative Spectrum of MT-45.  MT-45 at 10ppm; ppm error: 1.29.*Note 338 peak. 
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Figure 21: Representative Spectrum of Norbuprenorphine.  Norbuprenorphine at 10ppm; ppm error: 3.1. *Note 338 peak. 
Figure 22: Representative Spectrum of Norfentanyl.  Norfentanyl at 10ppm; ppm error: 4.71. 
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Figure 23: Representative Spectrum of U-47700.  U-47700 at 10ppm; ppm error: 0.423.
 
Figure 24: Representative Spectrum of Valeryl Fentanyl.  Valeryl Fentanyl at 10ppm; ppm error:-3.01. 
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Figure 25: Representative Spectrum of W-15.  W-15 at 10ppm; ppm error: -1.26. 
 
Figure 26: Representative Spectrum of W-18.  W-18 at 10ppm; ppm error: -2.86. *Note 338 peak.  
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Table 2: Compounds of Interest’s Precursor Ions and Characteristic Fragmentation Ions.  
Compounds of Interest Molecular 
Formula 
Precursor 
Ion 
Characteristic 
Fragmentation Ions 
Attributed to: 
4-ANPP C19H24N2 281.2012 188 
105 
Loss of C6H6N 
Loss of C11H16N2 
6-Mononacetylmorphine C19H21NO4 328.1543 268 
211 
Loss of C2H3O2 
Loss of C2H3O2 and C3H7N 
Acetyl Fentanyl C21H26N2O 323.2118 188 
105 
Loss of C8H8NO 
Loss of C13H13N2O 
AH-7921 C16H22Cl2N2O 329.1182 284, 286 
189, 191 
172,174 
Loss of C2H6N 
Loss of C9H18N 
Loss of C9H19N2 
Beta-
Hydroxythiofentanyl 
C20H26N2O2S 359.1788 341 
210 
192 
Loss of OH (H2O) 
Loss of C9H10NO 
Loss of C9H10NO and OH (H2O) 
Buprenorphine C29H41NO4 468.3108 450 
418 
Loss of OH (H2O) 
Loss of 3(OH) (3(H2O)) 
Butyryl Fentanyl C23H30N2O 351.2431 188 
105 
Loss of C10H12NO 
Loss of C15H21N2O 
Desomorphine C17H21NO2 272.1645 215 Loss of C3H7N 
Fentanyl C22H28N2O 337.2274 188 
105 
Loss of C9H10NO 
Loss of  C14H19N2O 
Furanyl Fentanyl C24H26N2O2 375.2067 188 
105 
Loss of C11H8NO2 
Loss of C16H17N2O2 
Heroin C21H23NO5 370.1649 328 
310 
286 
268 
211 
Loss of C2H3O 
Loss of C2H3O2 
Loss of 2(C2H3O2) 
Loss of  C2H3O and C2H3O2 
Loss of  2(C2H3O2) and C3H7N 
Morphine C17H19NO3 286.1438 268 
211 
Loss of OH (H2O) 
Loss of OH (H2O) and C3H7N 
MT-45 C24H32N2 349.2638 181 
169 
Loss of C10H19N2 
Loss of C14H13 
Norbuprenorphine C25H35NO4 414.2639 396 
364 
Loss of OH (H2O) 
Loss of 3(OH) (3(H2O)) 
Norfentanyl C14H20N2O 233.1648 177 
150 
Loss of C3H5O 
Loss of C5H10N 
U-47700 C16H22Cl2N2O 329.1182 284, 286 
203, 204 
172, 174 
Loss of C2H9N 
Loss of C8H16N 
Loss of C9H23N2 
Valeryl Fentanyl C24H32N2O 365.2587 188 
105 
Loss of C11H14NO 
Loss of C16H23N2O 
W-15 C19H21ClN2O2S 377.1085 105 
111 
Loss of C13H17N2O2S 
Loss of C11H12ClN2O2S 
W-18 C19H20ClN3O4S 422.0936 392 
273 
120 
Loss of 2(OH) (2(H2O)) 
Loss of C8H8NO2 
Loss of C13H16N2O2ClS 
30 
9 4 . 0 3 7 2  
1 2 1 . 0 5 0 9  
1 4 9 . 0 2 3 0  
1 8 8 . 1 4 4 0  
2 9 0 . 0 2 1 9  
3 2 2 . 0 4 8 8  
3 3 7 . 2 2 7 7  
3 3 8 . 3 4 2 9  
6 2 2 . 0 2 9 0  
0
2 5 0 0
5 0 0 0
7 5 0 0
1 0 0 0 0
1 2 5 0 0
1 5 0 0 0
1 7 5 0 0
2 0 0 0 0
2 2 5 0 0
5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0 6 0 0
M a ss
R E T  ( 0 0 . 1 7 9 1 6 )
A
m
p
li
t
u
d
e
m / z
C u r v e  1
Figure 27: Fentanyl Spectrum at 1ppm with Suspected Contamination. 
 
3.2 Carryover Study Results 
 In this study, solvent blanks of LC/MS grade water were pipetted onto mesh 
target screens in between compounds of interest.  These spectra from the solvent blanks 
did not contain any persisting precursor ions or characteristic fragmentation ions from the 
compounds of interest.  However, closer evaluation of the spectra revealed specific m/z 
peaks (149, 290, and 338).  These peaks are thought to be attributed to the presence of 
phthalates present in the pipette tip.  When pipetting samples onto targeted mesh screens 
pipette tips scratch the surface of screens, leaving phthalates residue behind, which are 
then detected. 
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For future studies and testing, pipet tips were not scratched along surface of mesh 
target screens.  These peaks are not present at high concentration or in forensic case 
seized drug casework samples but should be noted as possible contamination especially at 
low concentrations. 
3.3 Limit of Detection Study Results 
 Limit of detection (LOD) was determined to be 0.1 ppm. LOD was determined by 
analyzing standards at 0.1 ppm, 0.05 ppm, and 0.01 ppm concentrations a minimum of 10 
replicates.  At 0.1 ppm, there was only one mass accuracy failure for all 19 compounds, 
but no characteristic fragment identification failure.  At concentrations of 0.05 and 
0.01ppm, there was fragment identification failure (signal below 500 counts) over 50% of 
the time. 
3.4 Repeatability Study Results 
 For the 20 replicates (10ppm and 1ppm), successful criteria range was 
established; precursor ion within ±10 ppm error, and characteristic fragmentation 
identification with signal above 500 counts.  Analysis reveals 93% at 10 ppm and 83% at 
1ppm of compounds of interest were identified within the successful criteria range.  The 
following figures (Figure 28 - Figure 46) depicts the 19 compounds of interest’s 
repeatability study. 
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Figure 28: Repeatability Study: 4-ANPP.  Samples were successfully identified in both 1ppm (100%) and 10ppm 
(100%) concentrations with no samples outside of acceptable criteria range. 
 
Figure 29: Repeatability Study: 6-MAM.  Samples were successfully identified in both 1ppm (80%) and 10ppm 
(100%) concentrations with four sample outside of acceptable criteria range at 1ppm concentration (-10.3,-10.5, 11.6, 
and 12 ppm error). 
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Figure 30: Repeatability Study: Acetyl Fentanyl.  Samples were successfully identified in both 1ppm (95%) and 
10ppm (80%) concentrations with one sample outside of acceptable criteria range at 1ppm concentration (10.9 ppm 
error) and four samples outside of acceptable criteria range at 10 ppm concentration (10.4, 10.6, 11.6 and 12.2 ppm 
error) 
 
Figure 31: Repeatability Study: AH-7921.  Samples were successfully identified in both 1ppm (75%) and 10ppm 
(100%) concentrations with five samples outside of acceptable criteria range at 1ppm concentration (-16, -13.7, 12.2, 
12.5 and 12.5 ppm error). 
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Figure 32: Repeatability Study: Beta-hydroxythiofentanyl.  Samples were successfully identified in both 1ppm 
(95%) and 10ppm (100%) concentrations with one sample outside of acceptable criteria range at 1ppm concentration 
(10.7ppm error). 
 
Figure 33: Repeatability Study: Buprenorphine.  Samples were successfully identified in both 1ppm (70%) and 
10ppm (90%) concentrations with six samples outside of acceptable criteria range at 1ppm concentration (-14.6, -11, 
11.9, 12.4, 14.3, and 15.6 ppm error) and two samples outside acceptable critera range at 10ppm concentration ( -12.9 
and -10 ppm error). 
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Figure 34: Repeatability Study: Butyryl Fentanyl.  Samples were successfully identified in both 1ppm (80%) and 
10ppm (95%) concentrations with four samples outside of acceptable criteria range at 1ppm concentration (10.3, 12.2, 
12.8, 13.7) and one sample ouside of acceptable criteria at 10ppm concentrtaion (13 ppm error). 
 
Figure 35: Repeatability Study: Desomorphine.  Samples were successfully identified in both 1ppm (100%) and 
10ppm (95%)concentrations with one sample outside of acceptable criteria range at 10ppm concentration (-10.4 ppm 
error). 
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Figure 36: Repeatability Study: Fentanyl.  Samples were successfully identified in both 1ppm (90%) and 10ppm 
(100%) concentrations with one sample outside of acceptable criteria range at 1ppm concentration (10.1ppm error). 
 
Figure 37: Repeatability Study: Furanyl Fentanyl.  Samples were successfully identified in both 1ppm (75%) and 
10ppm (70%) concentrations with five samples outside of acceptable criteria range at 1ppm concentration (10.8, 11.4, 
11.9, 11.9, and 14.5 ppm error).and six samples outside of acceptable criteria range at 10ppm concentration (10.3, 10.3, 
11.6, 11.8, 11.9, and 13.5 ppm error). 
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Figure 38: Repeatability Study: Heroin.  Samples were successfully identified in both 1ppm (90%) and 10ppm 
(100%) concentrations with two samples outside of acceptable criteria range at 1ppm concentration (10.5 and 11.6 ppm 
error). 
 
Figure 39: Repeatability Study: Morphine.  Samples were successfully identified in both 1ppm (95%) and 10ppm 
(100%) concentrations with one sample outside acceptable criteria range at 1ppm concentration (10.6 ppm error). 
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Figure 40: Repeatability Study: MT-45.  Samples were successfully identified in both 1ppm (60%) and 10ppm 
(95%) concentrations with eight samples outside of acceptable criteria range at 1ppm concentration (10.1, 10.7, 11.1, 
13.4, 15.2, 15.3, and 15.4 ppm error).and one sample outside of acceptable criteria range at 10ppm concentration (10.7 
ppm error). 
 
Figure 41: Repeatability Study: Norbuprenorphine.  Samples were successfully identified in both 1ppm (70%) and 
10ppm (80%) concentrations with six samples outside acceptable criteria range at 1ppm concentration (10.2, 10.5, 11.1, 
12.3, 15, and 18.1 ppm error) and four samples outside acceptable criteria range at 10ppm concentration (11.1, 12.3, 
12.6, and 12.9). 
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Figure 42: Repeatability Study: Norfentanyl.  Samples were successfully identified in both 1ppm (90%) and 10ppm 
(100%) concentrations with two samples outside of acceptable criteria range at 1ppm concentration (11.6 and 12.1 ppm 
error). 
 
Figure 43: Repeatability Study: U-47700.  Samples were successfully identified in both 1ppm (85%) and 10ppm 
(100%) concentrations with three samples outside of acceptable criteria range at 1ppm concentration (-11.5, 10.87, and 
12.8 ppm error). 
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Figure 44: Repeatability Study: Valeryl Fentanyl.  Samples were successfully identified in both 1ppm (100%) and 
10ppm (100%) concentrations with no samples outside of acceptable criteria range. 
 
Figure 45: Repeatability Study: W-15.  Samples were successfully identified in both 1ppm (65%) and 10ppm (85%) 
concentrations with seven samples outside of acceptable criteria range at 1ppm concentration (-10.89, -10.85, 10.36, 
10.5, 11.63, 14.6, 16.8 ppm error) and three samples outside the acceptable criteria range at 10ppm concentration (12.6, 
13.8, and 14.78 ppm error). 
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Figure 46: Repeatability Study: W-18.  Samples were successfully identified in both 1ppm (70%) and 10ppm (90%) 
concentrations with six samples outside of acceptable criteria range at 1ppm concentration (10.01, 10.25, 11.63, 12.86, 
and 13.88 ppm error) and two samples outside of acceptable criteria range at 10ppm concentration (10.85 and 11.2 ppm 
error). 
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3.5 Forensic Seized Drug Casework Samples Results 
 Sixty-four forensic seized drug casework samples were analyzed using DSA-
TOFMS.  The results of the analysis are presented in Table 3.  Heroin was qualitatively 
identified in 89% of samples with ppm error range from -13 to -0.0348.  Heroin and 
fentanyl was qualitatively identified in 1% of samples; a ppm error range could not be 
determined.  Fentanyl was qualitatively identified in 4% of samples with ppm error range 
from -6.53 to 0.159.  Acetyl fentanyl was qualitatively identified in 3% of samples with a 
ppm error range of -5.86 and -4.18.  Furanyl Fentanyl was qualitatively identified in 3% 
of samples with ppm error range of -2.28 and -0.78.  Table 3 consists of forensic seized 
drug casework samples results. 
 
Figure 47 Case Sample 23 Furanyl Fentanyl.  First seized drug casework sample positively identified at the 
MHETL with precursor ion (-0.78 ppm error) and characteristic fragmentation ions. 
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Table 3: Forensic Solid Dose Casework Samples. Forensic seized drug casework samples positive for heroin (n= 57), 
fentanyl (n= 4), acetyl fentanyl (n= 2), and furanyl fentanyl (n= 2).  “X” represents negative results and “POS” 
represents positive results with corresponding ppm error.  “N/A” indicates could not be determined. 
Case 
Samples Heroin 
ppm 
error Fentanyl 
ppm 
error 
Acetyl 
Fentanyl 
ppm 
error 
Furanyl 
Fentanyl 
ppm 
error 
1 POS -13 X X X X X X 
2 POS -8.23 X X X X X X 
3 POS -4.38 X X X X X X 
4 POS -3.19 X X X X X X 
5 POS -5.36 X X X X X X 
6 POS -3.11 X X X X X X 
7 POS -0.94 X X X X X X 
8 POS -3.65 X X X X X X 
9 POS -1.97 X X X X X X 
10 POS 6.45 X X X X X X 
11 POS 1.09 X X X X X X 
12 POS -0.615 X X X X X X 
13 POS -0.805 X X X X X X 
14 POS -5.95 X X X X X X 
15 POS -5.06 X X X X X X 
16 POS -11.9 X X X X X X 
17 POS -2.05 X X X X X X 
18 X X POS 1.74 X X X X 
19 POS -6.6 X X X X X X 
20 X X POS 0.159 X X X X 
21 POS -0.507 X X X X X X 
22 POS -2.08 X X X X X X 
23 X X X X X X POS -0.78 
24 POS -3.73 X X X X X X 
25 POS 0.089 X X X X X X 
26 POS -2.19 X X X X X X 
27 POS 0.0348 X X X X X X 
28 POS -0.697 X X X X X X 
29 POS -0.29 X X X X X X 
30 POS -1.18 X X X X X X 
31 POS 0.739 X X X X X X 
32 POS -0.263 X X X X X X 
33 POS -0.67 X X X X X X 
34 POS 1.85 X X X X X X 
35 POS -2.62 X X X X X X 
36 POS 1.06 X X X X X X 
44 
Case 
Samples Heroin 
ppm 
error Fentanyl 
ppm 
error 
Acetyl 
Fentanyl 
ppm 
error 
Furanyl 
Fentanyl 
ppm 
error 
37 X X X X X X POS -2.28 
38 POS N/A POS N/A X X X X 
39 POS -2.94 X X X X X X 
40 POS -1.08 X X X X X X 
41 POS -0.182 X X X X X X 
42 POS -1.05 X X X X X X 
43 POS -8.25 X X X X X X 
44 POS 0.143 X X X X X X 
45 POS -0.967 X X X X X X 
46 POS 0.82 X X X X X X 
47 POS 5.79 X X X X X X 
48 POS -2.38 X X X X X X 
49 POS 0.197 X X X X X X 
50 POS -2.7 X X X X X X 
51 POS -2.08 X X X X X X 
52 POS -3.78 X X X X X X 
53 POS -4.35 X X X X X X 
54 X X X X POS -5.86 X X 
55 POS -0.0736 X X X X X X 
56 POS -0.507 X X X X X X 
57 POS -0.0194 X X X X X X 
58 POS -8.23 X X X X X X 
59 POS -1.32 X X X X X X 
60 X X POS -6.53 X X X X 
61 X X X X POS -4.18 X X 
62 POS -13.2 X X X X X X 
63 POS -3.05 X X X X X X 
64 POS -3.08 X X X X X X 
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 The mass accuracy of the DSA-TOFMS was closely evaluated for the forensic 
seized drug casework samples positively identified as heroin.  Figure 27 demonstrates the 
ppm error range for the heroin seized drug casework samples.  The DSA-TOFMS was 
able to positively identify heroin within the successful criteria range with mass accuracy 
in 95% of heroin samples.  The mass accuracy for 5% of the heroin samples were outside 
successful criteria range with ppm error ±15 ppm. 
 
Figure 48: Error for Heroin Solid Dose Casework Samples.  Fifty-seven heroin casework samples were 
qualitatively identified.  Three of the samples had a ppm error above ±10 with the presence of precursor ion and 
fragmentation ions. (5%).  Fifty-four out of the fifty-seven (95%) samples had a ppm error below ±10 with the presence 
of precursor ion and fragmentation ions. 
 
3.6. Forensic Urine Casework Samples 
 The forensic urine casework samples acceptable criteria for mass accuracy must 
be within the ± 10 ppm error range and above 500 counts.  Analysis displayed the 
limitations of DSA-TOFMS as only twelve of the forty compounds of interest were 
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present and only four of the twelve were within the acceptable criteria range.  Table 4 
through Table 9 contains these results. 
Table 4: Urine Case Sample 1 Results.  Comparison of GC/MS results and DSA-TOFMS 
results. 
GC/MS Results 4-ANPP, furanyl fentanyl, morphine, codeine, methadone, 
EDDP, alprazolam, hydroxyalprazolam 
DSA-TOFMS Results furanyl fentanyl (5.45 ppm error; below 500 counts) 
methadone (-5.97ppm error; above 500 counts) 
EDDP (1.12 ppm error; above 500 counts 
 
Table 5 Urine Case Sample 2 Results.  Comparison of GC/MS results and DSA-TOFMS 
results. 
GC/MS Results fentanyl, acetyl fentanyl, 6-MAM, morphine, 
norbuprenorphine, codeine, cocaine, benzoylecgonine, 
amphetamine  
DSA-TOFMS Results fentanyl (8.22 ppm error; below 500 counts) 
acetyl fentanyl (4.01ppm error; below 500 counts) 
cocaine (5.04 ppm error; above 500 counts) 
benzoylecgonine (6.05 ppm error; above 500 counts) 
 
Table 6 Urine Case Sample 3 Results.  Comparison of GC/MS results and DSA-TOFMS 
results. 
GC/MS Results fentanyl, acetyl fentanyl, 6-MAM, morphine, codeine, 
carboxy THC, tramadol  
DSA-TOFMS Results fentanyl (9.23 ppm error; below 500 counts) 
 
Table 7 Urine Case Sample 4 Results.  Comparison of GC/MS results and DSA-TOFMS 
results. 
GC/MS Results fentanyl, acetyl fentanyl, norfentanyl, oxycodone, 
oxymorphone 
DSA-TOFMS Results fentanyl (-7.54 ppm error; below 500 counts) 
oxycodone (1.01 ppm error; below 500 counts) 
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Table 8 Urine Case Sample 5 Results.  Comparison of GC/MS results and DSA-TOFMS 
results. 
GC/MS Results 6-MAM, morphine, codeine, carboxy-THC 
DSA-TOFMS Results codeine (-26.6 ppm error; below 500 counts) 
 
Table 9 Urine Case Sample 6 Results.  Comparison of GC/MS results and DSA-TOFMS 
results. 
GC/MS Results Fentanyl, 6-MAM, morphine, codeine, carboxy-THC, 
ketamine, norketamine 
DSA-TOFMS Results fentanyl (15.6 ppm error; below 500 counts) 
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4. DISCUSSION AND CONCLUSION 
4.1 Summary of Results 
 All 19 compounds of interest were successfully evaluated and precursor ion and 
characteristic fragmentation ions were identified.  Settings were optimized to provide 
quality spectra for all compounds of interest. 
 In the carryover study, compounds of interest did not persist in the capillary inlet 
nor were the compounds detected in subsequent samples.  However, suspected 
contamination peaks from the pipette tips were noted.  This is most likely caused by the 
scratching of pipette tips onto mesh target screens.  In the future, glass pipette tips could 
be considered if compounds of interest have 149, 290, or 338 m/z as precursor ions or 
characteristic fragmentation ions.  These peaks did not interfere with the compounds 
investigated in this study, however, the large 338 peak seen in Figure 27 would cause 
confusion to the precursor ion in an unknown casework sample containing fentanyl. 
 The limit of detection of the DSA-TOFMS was determined to be 0.1 ppm (100 
ng/mL).  Lower concentrations are not expected to be seen in forensic seized drug 
casework samples, and, therefore, the DSA-TOFMS is a reliable technique to 
qualitatively identify illicit substances in forensic seized drug casework samples. 
 In the repeatability study, analysis reveals on average 93% of compounds of 
interest at 10 ppm and 83% of compounds at 1ppm were identified within the successful 
criteria range.  However, this work was completed on instrument that was adjacently 
placed next to an air conditioner.  The TOFMS flight tube is not insulated and is 
susceptible to temperature changes which can impact the accurate mass obtained.  The 
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variability in these results may be due to the inconsistent temperature of the laboratory 
and therefore variable temperatures in the flight tube.  However, this variability can be 
avoided through calibration of this instrument multiple times throughout the day and 
other manufactures have insulated flight tubes as a preventative measure. In more stable 
and consistent conditions, a higher stringency for error rate (such as 5ppm error) could be 
utilized and decrease the potential for misidentification in forensic casework samples,  
 In this study, a simple and fast sample preparation technique was utilized to 
successfully identify 64 forensic seized drug casework samples.  The two casework 
samples which positively identified furanyl fentanyl was the first time the Maine HETL 
had encountered this compound in seized drug casework samples.  Therefore, no GC/MS 
library was available.  The DSA-TOFMS was used to abbreviate the identification 
process and allowed for the analysis of this true unknown unknown compound in 20 
seconds.  This highlights the advantage of having DSA-TOFMS available in a forensic 
laboratory for seized drug casework samples. 
 Analysis of the six urine casework samples illustrated the limitations when using 
DSA-TOFMS to qualitatively identify lower than 0.1 ppm concentrations of analytes in a 
complex matrix.  The DSA-TOFMS was unable to identify all compounds in the urine 
casework samples.  Concentrations in urine casework samples, such as urine or blood, are 
lower than 0.1ppm and therefore this instrumentation is not ideal for the analysis of urine 
specimens unless the quantities were significant.  It appears for urine specimens’ 
analysis, chromatography is the superior technique.  However, the sample preparation 
utilized in this study may have been inadequate in preparing the sample for analysis.  
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Further investigation of dilutions, syringe filters with varying size, and/or solid phase 
extraction sample preparation techniques should be performed to determine if DSA-
TOFMS could effectively be used for biological specimens.  
4.2 Future Direction 
 In the future, a repeatability study in more stable and consistent conditions should 
be conducted using DSA-TOFMS.  Also, new synthetic opiates, such as carfentanil and 
4-fluoroisobutyryl fentanyl, and other designer drug classes; such as synthetic cathinones 
and cannabinoids, should be evaluated on the DSA-TOFMS to determine optimal 
settings.  A variety of sample preparation techniques for biological specimen should be 
further investigated as well. A larger sample size should also be investigated as the 
sample size of six in this study is not an accurate representation of casework samples.  
Blood was not evaluated in this study, however due to the complexity of the matrix it 
may prove challenging to work with using the DSA-TOFMS.  However, LC-TOFMS 
would be a viable option for both urine and blood samples. 
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